SCHEMBL4046324

SCHEMBL4046324

[c]1c[nH]c(-c2cccc(-c3ccccc3)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.40
GP6 Q9HCN6 1/20 0.40
NISCH Q9Y2I1 1/20 0.39
MAOA P21397 1/20 0.36
NOTUM Q6P988 1/20 0.36
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
HTR1A P08908 1/20 0.35
HTR7 P34969 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
NPC1 O15118 1/20 0.34
DHODH Q02127 1/20 0.34
IMPDH2 P12268 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PSMB8 P28062 1/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4041670 0.86 MTOR (0.41) NISCHNOTUMNPC1CYP1A2CYP3A4
SCHEMBL403894 0.86 MTOR (0.43) NISCHNPC1CYP1A2CYP3A4ALDH1A1
SCHEMBL4043823 0.84 MKNK1 (0.41) CYP1A2CYP3A4CYP2C9CYP2C19ATM
SCHEMBL4041568 0.80 HSD17B1 (0.47) CYP1A2CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL4049207 0.80 ALDH1A1 (0.47) NPC1CYP1A2ALDH1A1HTT
SCHEMBL2091213 0.80 IDO1 (0.45) NISCHNOTUMNPC1CYP1A2CYP2C9
SCHEMBL2650383 0.80 IDO1 (0.49) NOTUMNPC1ALDH1A1
SCHEMBL4044973 0.78 ASIC3 (0.45) NISCHHTR1AHTR7CYP1A2CYP3A4
SCHEMBL4050231 0.78 CYP1A2 (0.40) NISCHNOTUMIMPDH2CYP1A2CYP3A4
SCHEMBL4044851 0.76 CYP11B1 (0.45) NISCHNOTUMNPC1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589096-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-15 US disclosed
EP-1566384-B1 NOVEL AZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2009-06-17 EP disclosed
US-20080188507-A1 Novel azole derivatives MSD K.K. (JP) 2008-08-07 US disclosed
US-7365079-B2 Azole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-29 US disclosed
US-20060111380-A1 Novel azole derivatives MSD K.K. (JP) 2006-05-25 US disclosed
EP-1566384-A1 NOVEL AZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188507-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R KMO 175/4885GP6 3380/4885NISCH 1902/4885
US-20060111380-A1 Novel azole derivatives NPY1R, NPY5R, NPY2R KMO 172/4885GP6 3527/4885NISCH 1980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.